Sail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D’Amelio to Its Board
Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.
- Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.
- At Lucent, he played a critical role in its spinout from AT&T.
- “I’m honored to be joining the Sail Biomedicines Board of Directors at a pivotal time for the company,” said Mr. D’Amelio.
- “Sail’s vision and platform, which builds on over eight years of experimentation, represents an exciting opportunity to generate new medicines and forge innovative relationships with partners.